Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock based on expected benefits from the upcoming market conditions in the livestock sector [2][3]. Core Insights - The livestock segment of the company experienced rapid growth in 2023, with revenues reaching 508 million yuan, a year-on-year increase of 28%. The company has established strategic partnerships with major livestock farming groups and is expanding its marketing network in the dairy cow market [1]. - The company has also made significant strides in the pet health sector, launching a joint venture to capitalize on the growing pet market and aiming to create a leading domestic brand [1]. - The overall revenue for 2023 was 2.249 billion yuan, reflecting a 7.9% increase year-on-year, with a net profit of 453 million yuan, up 30.64% from the previous year [5]. Summary by Sections Livestock Business Performance - The livestock segment's revenue growth is attributed to a diverse product portfolio in vaccines, pharmaceuticals, and feed additives, with competitive advantages in the industry [1]. - The company is actively expanding its presence in the dairy cow market and enhancing its marketing strategies [1]. Pet Health Sector Development - The establishment of a joint venture with Ruiyi Biotechnology aims to leverage opportunities in the pet health market, with plans for independent operations to accelerate growth [1]. - The company has launched new products, including a cat trivalent vaccine, which has received positive market feedback, and is developing a quadrivalent vaccine in collaboration with another technology firm [14]. Financial Projections - The net profit forecasts for 2024 and 2025 have been slightly adjusted to 549 million yuan and 674 million yuan, respectively, reflecting a decrease of 5.34% and 1.32% from previous estimates. The forecast for 2026 is set at 817 million yuan [2]. - The earnings per share (EPS) are projected to be 1.18, 1.45, and 1.75 yuan for the years 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios of 14, 11, and 9 [2].

Investment Rating - The report maintains a "Strong Buy" rating for the company [5][20]. Core Views - The company achieved a revenue of 2.249 billion, a year-on-year increase of 7.9%, and a net profit attributable to shareholders of 453 million, up 30.64% year-on-year [5]. - The livestock business showed strong performance, driving overall growth despite a challenging market environment [5]. - The company is focusing on the top 100 domestic livestock farming groups, providing comprehensive health solutions, and has established strategic partnerships with leading clients [5]. - The gross margin improved to 49.69%, an increase of 1.25 percentage points year-on-year, with a net profit margin of 22.72%, up 4.79 percentage points year-on-year [5]. - The company plans to acquire 100% of Baoding Shoujun, indirectly holding 55.2% of a foot-and-mouth disease vaccine company, which is expected to enhance its vaccine segment [5]. Financial Summary - Revenue projections for 2024-2026 are 3.028 billion, 3.462 billion, and 3.887 billion, respectively, with year-on-year growth rates of 34.6%, 14.3%, and 12.3% [21]. - Net profit attributable to shareholders is forecasted to be 528 million, 624 million, and 696 million for 2024-2026, with growth rates of 16.6%, 18.1%, and 11.6% [21]. - Earnings per share (EPS) are expected to be 1.13, 1.34, and 1.49 for 2024-2026 [21]. - The current stock price corresponds to a 14 times price-to-earnings (PE) ratio for 2024, which is considered low compared to the target PE range of 18-20 times [5][21].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 20.90 CNY over the next six months [1]. Core Insights - The company achieved a revenue of 2.25 billion CNY in 2023, representing a year-on-year growth of 7.9%, and a net profit attributable to shareholders of 450 million CNY, up 30.6% year-on-year [1]. - The main business segments showed steady growth, with the pet segment's layout progressing, including the launch of a cat trivalent vaccine and the completion of clinical trials for a dog quadrivalent vaccine [1][2]. - The company has increased its R&D investment to 233 million CNY, accounting for 10.35% of its revenue, focusing on developing cutting-edge pet products [2]. - The company is actively expanding its portfolio in the African swine fever vaccine market and enhancing its competitiveness in the foot-and-mouth disease vaccine market through strategic acquisitions [3]. Revenue and Profit Summary - In Q4 2023, the company reported a revenue of 660 million CNY, a year-on-year increase of 8.9%, and a net profit of 180 million CNY, up 57.7% year-on-year [1]. - The sales revenue from the formulation and raw materials business reached 1.08 billion CNY, growing by 11.20% year-on-year, while the poultry biological products segment generated 928 million CNY, up 3.64% [1][4]. Financial Forecast - The company is projected to achieve earnings per share (EPS) of 1.10 CNY, 1.35 CNY, and 1.61 CNY for the years 2024, 2025, and 2026, respectively, with corresponding dynamic price-to-earnings ratios of 13, 11, and 9 [3][4]. - Revenue is expected to grow significantly, with forecasts of 2.79 billion CNY in 2024, 3.40 billion CNY in 2025, and 4.06 billion CNY in 2026, reflecting growth rates of 24.75%, 22.48%, and 20.00% respectively [10]. Strategic Developments - The company signed a cooperation agreement for the development of a recombinant African swine fever vaccine and plans to acquire 100% of Baoding Shoujun for 230 million CNY, enhancing its production capacity for foot-and-mouth disease vaccines [3][4]. - The company has received several new veterinary drug registration certificates, including for a pet anesthetic, marking a significant step in breaking the monopoly of imported products in China [2].

《【兴证农业】瑞普生物 2023Q3 业绩点评：三季度稳中向好，股 权激励目标或能达成》 《【兴证农业】瑞普生物 2023H1 业绩点评：化药板块盈利能力修 复，宠物板块打造新增长曲线》 2023-09-06 《【兴证农业】瑞普生物 2022 年 年报点评：22Q4 业绩环比提升， 未来盈利空间持续释放》2023- 04-02 公司点评报告(带市场行情) | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------|---------------------|---------------------|-------|---------------|---------------------------------------------|--------|------------------------|--------|-------------| | 附表 ＄ 资产负债表 ...

瑞普生物（ [Table_StockNameRptType] 300119） 公司研究/公司点评 敬请参阅末页重要声明及评级说明 证券研究报告 | --- | --- | --- | --- | --- | |-------------------|-------|------------------------|-------|-------| | 主要财务指标 | 2023A | 2024E | 2025E | 2026E | | 营业收入 | | 2249 2640 3128 3659 | | | | 收入同比（ % ） | 7.9% | 17.4% | 18.5% | 17.0% | | 归属母公司净利润 | | 453 502 664 853 | | | | 净利润同比（ % ） | 30.6% | 10.7% | 32.5% | 28.5% | | 毛利率（ % ） | 49.7% | 52.3% | 52.3% | 52.4% | | ROE （ % ） | 10.1% | 10.1% | 11.8% | 13.1% | | 每股收益（元） | | 0.98 1.08 1.42 1.83 | | ...

Investment Rating - The report maintains a "Buy" rating for the company [4][12]. Core Views - The company achieved a revenue of 2.249 billion yuan in 2023, representing a year-on-year increase of 7.90%, and a net profit attributable to shareholders of 453 million yuan, up 30.64% year-on-year [1]. - The company is entering a harvest period for its R&D investments, with multiple new products making progress, including a self-developed cat trivalent vaccine and a dog quadrivalent vaccine [1]. - The acquisition of 100% equity in Baoding Shoujun for 230 million yuan will allow the company to indirectly hold 55.20% of the domestic foot-and-mouth disease vaccine producer, Betway Antai, enhancing its livestock business [1]. Financial Performance - In Q4 2023, the company reported a revenue of 662 million yuan, a year-on-year increase of 8.94%, and a net profit of 179 million yuan, up 57.68% year-on-year [1]. - The company’s sales revenue from formulations and raw materials reached 1.084 billion yuan, growing by 11.20% year-on-year, while the revenue from poultry biological products was 928 million yuan, up 3.64% [4]. - The gross profit margin improved by 1.25 percentage points year-on-year, and the net profit margin after deducting non-recurring items increased by 0.69 percentage points year-on-year [4]. Revenue and Profit Forecast - The projected revenues for 2024, 2025, and 2026 are 2.772 billion yuan, 3.113 billion yuan, and 3.531 billion yuan, respectively, with growth rates of 23.24%, 12.33%, and 13.41% [3][7]. - The forecasted net profits for the same years are 516 million yuan, 617 million yuan, and 722 million yuan, with year-on-year growth rates of 13.90%, 19.53%, and 17.08% [3][7]. Market Data - The current stock price is 14.43 yuan, with a market capitalization of approximately 6.73 billion yuan [1][12]. - The stock has a 52-week price range of 11.55 to 22.95 yuan [1].

Financial Performance - The company's operating revenue for 2023 was ¥2,248,962,053.98, representing a 7.90% increase compared to ¥2,084,250,399.00 in 2022[23]. - Net profit attributable to shareholders for 2023 was ¥452,942,064.27, a 30.64% increase from ¥346,698,684.97 in 2022[23]. - The net profit after deducting non-recurring gains and losses was ¥318,420,957.50, up 13.43% from ¥280,715,394.08 in 2022[23]. - The total assets at the end of 2023 reached ¥6,595,941,501.08, an 8.02% increase from ¥6,106,273,672.25 at the end of 2022[23]. - The basic earnings per share for 2023 was ¥0.9772, a 30.50% increase compared to ¥0.7488 in 2022[23]. - The company reported a net cash flow from operating activities of ¥378,196,328.60, a slight decrease of 2.90% from ¥389,486,980.07 in 2022[23]. - The company achieved a revenue of 2.249 billion yuan in 2023, representing a year-on-year growth of 7.90%[88]. - The net profit attributable to the parent company was 453 million yuan, an increase of 30.64% compared to the previous year[88]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 318 million yuan, up 13.43% year-on-year[88]. Market Position and Strategy - The company has a strategic focus on expanding its market presence and enhancing its product development capabilities[4]. - The company aims to strengthen its market position through strategic expansions and potential acquisitions in the veterinary medicine industry[50]. - The company is focusing on the pet health market, with plans to establish itself as a leading domestic brand, leveraging the growing pet population and market potential[73]. - The company is actively pursuing research and development of innovative veterinary products to meet the growing market demand and enhance its competitive edge in the industry[122]. - The company is committed to enhancing its supply chain advantages and improving production processes to reduce costs across all supply chain nodes[153]. - The company intends to deepen its poultry business and increase vaccine sales to further improve market share[153]. - The company is focusing on the pet industry, aiming to become a globally recognized brand by enriching its industry chain layout and building a channel ecosystem[153]. Research and Development - The company is committed to ensuring the accuracy and completeness of its financial reports, as stated by its management team[4]. - The company has a strong R&D team, including 8 national-level talents and 23 provincial-level experts, enhancing its innovation capabilities across various scientific fields[74]. - R&D investment increased from 15.16 million in 2021 (7.55% of revenue) to 23.28 million in 2023 (10.35% of revenue), driving product innovation and market expansion[71]. - The company has developed multiple key technology platforms for drug research, including new drug design and screening, which have led to dozens of innovative inventions in new drug crystal forms and compound structures[80]. - The company has established long-term cooperative relationships with over 30 renowned research institutions, enhancing its innovation capabilities[76]. - The company has made significant advancements in mRNA vaccine development, with multiple products in strategic planning, enhancing its competitive edge in the market[78]. - The company is advancing its IPD R&D system transformation, focusing on product competitiveness and optimizing product launch processes for new products such as cat vaccines and antibiotics[155]. Product Development and Innovation - The company has obtained 15 new veterinary drug registration certificates for pets, including the first domestic cat trivalent vaccine, "Rui Miao Shu," which broke the reliance on imported vaccines[47]. - The company has developed a new generation of high-temperature resistant β-mannanase enzyme, enhancing gut health and nutrient utilization[54]. - The company’s new feed additive enzyme can improve nutrient absorption efficiency and save over 50 kcal/kg of feed energy[54]. - The company has successfully developed the "Porcine Circovirus Type 2 Genetic Engineering Subunit Vaccine," which is the first of its kind for the company and is currently in the new veterinary drug product approval stage[119]. - The company has developed a dual live vaccine for the prevention of Newcastle disease and infectious bronchitis, which can be stored at 2-8°C for up to 24 months, addressing significant challenges in poultry farming[121]. - The company has developed a bivalent yolk antibody for the emergency prevention of duck viral hepatitis, enhancing its therapeutic antibody offerings for waterfowl[121]. - The company has successfully developed a new canine parvovirus serum, which induces endogenous interferon production and promotes antibody formation, filling a gap in the pet product line and addressing market needs[122]. Risks and Challenges - The company faces risks including animal epidemic risks, market competition risks, talent loss risks, and product development risks[4]. - The company is facing risks from animal epidemics, market competition, and potential talent loss, which could impact its operational performance[161][162][164]. - The company emphasizes the importance of a stable R&D team, as high-end talent is crucial for maintaining competitive advantages in the veterinary vaccine market[164]. - The company has implemented a cautious customer credit policy and established a bad debt provision policy based on industry comparisons and historical sales recovery data[167]. Governance and Management - The company maintains an independent business operation, with its board of directors, supervisory board, and internal institutions operating independently from the controlling shareholder[176]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[176]. - The company has established a performance evaluation and incentive system for its directors and senior management, ensuring transparency and compliance with regulations[183]. - The company has strengthened investor relations management and communication to protect the rights of investors, especially minority shareholders[173]. - The company has a structured approach to shareholder meetings, ensuring adequate time for shareholders to express their opinions and separate voting for minority shareholders on significant matters[174]. Awards and Recognition - The company has received multiple awards for its research and development efforts, including two National Science and Technology Progress Awards (second class) and several local awards[196]. - The company has been recognized as a leader in the industry, receiving accolades for its contributions to agricultural biotechnology and veterinary medicine[196]. - The company participated in the 17th China Listed Company Value Evaluation Activity and was recognized as one of the "Top 50 Value Companies on the Growth Enterprise Market"[173].

Investment Rating - The report maintains a "Recommend" rating for the company [1][13]. Core Insights - The company achieved a revenue of 2.25 billion yuan in 2023, representing a year-on-year growth of 7.9%, and a net profit attributable to shareholders of 450 million yuan, up 30.6% year-on-year [13]. - The livestock segment is experiencing rapid growth, while the pet segment faced some pressure due to weak downstream demand [13]. - The company has increased its R&D investment, with the R&D ratio rising from 7.6% in 2021 to 10.4% in 2023, driving continuous product iteration [13]. - The successful approval of the cat trivalent vaccine "Rui Miao Shu" marks a significant milestone, filling a gap in the domestic market [13]. - The acquisition of Biwei Antai extends the company's business coverage into the foot-and-mouth disease vaccine market, enhancing its overall solution capabilities for livestock enterprises [13]. - Future profit forecasts for 2024 to 2026 are 549 million, 639 million, and 737 million yuan respectively, with corresponding EPS of 1.18, 1.37, and 1.58 yuan, indicating a favorable outlook for the company [13]. Financial Projections - Revenue projections for 2024, 2025, and 2026 are 2.25 billion, 2.75 billion, and 3.11 billion yuan respectively, with growth rates of 7.9%, 22.4%, and 13.2% [4][10]. - The net profit attributable to shareholders is projected to be 549 million, 639 million, and 737 million yuan for the same years, with growth rates of 21.2%, 16.3%, and 15.5% [4][10]. - The company’s PE ratios are expected to decrease from 15 in 2024 to 9 in 2026, indicating improving valuation metrics [4][10].

天津瑞普生物技术股份有限公司 审计报告及财务报表 二○二三年度 信会师报字[2024]第 ZG10531 号 天津瑞普生物技术股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-6 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动 | 9-12 | | | 表 | | | | 财务报表附注 | 1-148 | 审计报告 信会师报字[2024]第 ZG10531 号 天津瑞普生物技术股份有限公司全体股东： 一、 审计意见 我们审计了天津瑞普生物技术股份有限公司（以下简称瑞普生 物）财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债 表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2024-021 天津瑞普生物技术股份有限公司 关于收购保定市收骏科技有限公司100%股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、天津瑞普生物技术股份有限公司（以下简称"公司"）拟以自有资金或自 筹资金收购保定市收骏科技有限公司（以下简称"保定收骏"、"标的公司"）100% 股权，收购完成后，保定收骏将纳入公司合并报表范围。 2、本次交易构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，不构成重组上市，无需取得有关部门批准。根据《深圳证券 交易所创业板股票上市规则》和《公司章程》的相关规定，本次关联交易尚需提 交公司股东大会审议。 3、受宏观经济波动、行业政策变化和竞争环境加剧等因素影响，保定收骏 未来盈利能力存在不确定性，敬请广大投资者注意投资风险。 一、关联交易概述 （一）交易内容 为补足公司口蹄疫疫苗产品布局，提升向家畜客户提供疫病整体解决方案的 能力，持续增强核心竞争力，公司于 2024 年 3 月 28 日在天津市签署《股权转让 协 ...